ERBB2 and breast cancer: A diagnostic technique with the potential to improve the preoperative identification of HER2-positive breast cancer patients with a pCR is HER2-targeted PET/CT-imaging using Zirconium-89 (89Zr)-radiolabeled trastuzumab.